Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pacemaker tweak may also lower blood pressure

NCT ID NCT04463121

Knowledge-focused Sponsor: BackBeat Medical Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether special pacing signals from a pacemaker can improve heart function and lower blood pressure in people who need a pacemaker and also have high blood pressure. Researchers will measure heart pressure and volume using a thin catheter inside the heart. The goal is to see if these signals can help control blood pressure while treating a slow heart rate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cardiac Neuromodulation Therapy (CNT) pacing signals delivered via a pacemaker device
What this could lead to
If successful, this could help develop a pacemaker-based treatment that lowers blood pressure while managing slow heart rate.
What could go wrong
This is a small, short-term study done just before a pacemaker implant, so results may not apply to long-term use or to broader patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

22 people

The number who actually took part.

Started

Aug 2020

Finished

Feb 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subject is ≥ 18 years of age 2. Subject requires implantation or replacement of a dual chamber pacemaker or requires an upgrade from a single chamber to a dual chamber pacemaker 3. Subject has known Hypertension 4. Subject is willing and able to comply with the study and procedures. Exclusion Criteria: 1. Subject has symptoms of heart failure, NYHA Class II or greater 2. Subject has significant (\>2+) mitral regurgitation, aortic regurgitation or aortic stenosis. 3. Subject has permanent atrial fibrillation 4. Subject has atrial fibrillation on the day of the study. 5. Subject has hypertrophic cardiomyopathy, restrictive cardiomyopathy or interventricular septal thickness ≥15 mm 6. Subject is on dialysis 7. Subject has a history of prior neurological events (stroke or TIA) within the past year or a neurological event (stroke or TIA) at any prior time that has resulted in residual neurologic deficit. 8. Subject has a history of autonomic dysfunction 9. Women who are pregnant or breast-feeding 10. Subject cannot or is unwilling to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bradycardia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Bradycardia hypertensive disorder Isolated Systolic Hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bradycardia Hypertension, systolic

Contacts and locations

Locations

  • Na Homolce Hospital

    Prague, 15030, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.